Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) traded up 1.7% during mid-day trading on Friday . The company traded as high as $14.55 and last traded at $14.52, with a volume of 110,873 shares. The stock had previously closed at $14.28.

Separately, Morgan Stanley reissued a “buy” rating and set a $17.00 price target on shares of Albany Molecular Research in a report on Friday, August 5th.

The stock’s 50-day moving average is $14.60 and its 200-day moving average is $14.63. The company’s market cap is $504.12 million.

Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. The company had revenue of $116.50 million for the quarter, compared to analysts’ expectations of $123.10 million. On average, analysts predict that Albany Molecular Research Inc. will post $1.09 EPS for the current year.

In other news, Director Kevin Oconnor sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total transaction of $72,050.00. Following the completion of the sale, the director now owns 52,955 shares in the company, valued at approximately $763,081.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.